Dutasteride (Avodart) and Benzodiazepines: Drug Interaction Guide

Why This Interaction Gets Flagged

Dutasteride and certain benzodiazepines are both metabolized through the cytochrome P450 3A4 (CYP3A4) enzyme system, which triggers automated alerts in pharmacy software. The dutasteride FDA-approved label identifies CYP3A4 as the primary metabolic pathway, alongside CYP3A5 [1]. Benzodiazepines such as alprazolam, midazolam, and triazolam depend heavily on CYP3A4 for clearance [2].

The overlap is pharmacokinetic, not pharmacodynamic. Dutasteride does not depress the central nervous system. It works by inhibiting 5-alpha reductase types I and II, blocking conversion of testosterone to dihydrotestosterone (DHT). Benzodiazepines enhance GABA-A receptor activity to produce sedation and anxiolysis. These mechanisms operate on entirely separate receptor systems. The concern is limited to whether the two drugs compete for the same metabolic enzyme in a way that raises blood levels of either compound. A pharmacokinetic analysis published in Clinical Pharmacology & Therapeutics confirmed that dutasteride is neither a clinically significant inhibitor nor inducer of CYP3A4 [3], which substantially limits the interaction potential.

How CYP3A4 Metabolism Creates the Overlap

Both drugs pass through CYP3A4, but the nature of that passage differs. The interaction is best understood by looking at enzyme kinetics and clinical concentration data.

Dutasteride is a substrate of CYP3A4 and CYP3A5. Its metabolism produces two major metabolites: 4'-hydroxydutasteride and 1,2-dihydrodutasteride. The drug has an extraordinarily long terminal half-life of approximately 5 weeks at steady state, reaching peak serum concentrations 2 to 3 hours after oral dosing [1]. This prolonged half-life means that even modest changes in metabolic clearance take weeks to manifest clinically.

CYP3A4-dependent benzodiazepines behave differently. Alprazolam has a half-life of 6 to 27 hours and is converted by CYP3A4 to alpha-hydroxyalprazolam [2]. Midazolam, frequently used as a CYP3A4 probe substrate in drug interaction studies, has a half-life of only 1.5 to 2.5 hours [4]. Short half-lives make these drugs more sensitive to enzyme competition.

The critical pharmacological point: dutasteride does not inhibit CYP3A4 at therapeutic concentrations. In vitro data from the FDA label show that dutasteride does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 [1]. Two drugs sharing a metabolic enzyme does not automatically create a meaningful interaction. Inhibition or induction of that enzyme by one of the drugs is what drives clinically significant changes in plasma levels.

Which Benzodiazepines Are Affected and Which Are Not

Not all benzodiazepines carry the same interaction profile. The distinction depends entirely on metabolic pathway.

CYP3A4-dependent benzodiazepines (theoretical interaction with dutasteride): Alprazolam, midazolam, and triazolam rely on CYP3A4 as their primary clearance route [2]. These are the agents that pharmacy interaction checkers flag when combined with other CYP3A4 substrates. A study in the Journal of Clinical Pharmacology demonstrated that potent CYP3A4 inhibitors like ketoconazole can increase alprazolam AUC by up to 3.98-fold [5]. Dutasteride, however, is not a CYP3A4 inhibitor, so this magnitude of change does not apply.

Glucuronidation-pathway benzodiazepines (no CYP3A4 interaction): Lorazepam, oxazepam, and temazepam bypass CYP3A4 entirely. They are metabolized through direct glucuronidation by UDP-glucuronosyltransferase (UGT) enzymes [2]. For patients already on dutasteride who need a benzodiazepine, these agents represent the cleanest pharmacokinetic option. This is particularly relevant for older men with benign prostatic hyperplasia (BPH), the population most likely to take dutasteride, who also have age-related reductions in CYP3A4 activity.

Diazepam occupies a middle category. It is metabolized by both CYP3A4 and CYP2C19, producing desmethyldiazepam [6]. The dual-pathway metabolism provides a buffer against significant interaction with any single CYP3A4 substrate.

Clinical Severity Rating and What the Evidence Shows

Major drug interaction databases classify the dutasteride-benzodiazepine combination as low risk. This is consistent with the available evidence.

The Lexicomp database rates the interaction as category C (monitor therapy) rather than category D (consider modification) or category X (avoid combination) [7]. Clinical Pharmacology (Elsevier) assigns a minor severity rating. No published case reports document adverse events specifically from combining dutasteride with any benzodiazepine.

The CombAT trial (N=4,844), the largest randomized controlled trial of dutasteride in BPH, permitted concurrent benzodiazepine use and did not report increased adverse events in patients taking both medications over 4 years of follow-up [8]. While the trial was not designed to study this interaction specifically, the absence of safety signals in a population of nearly 5,000 men provides real-world reassurance.

Data from the dutasteride FDA label further support this assessment. In clinical trials enrolling over 8,000 men with BPH, the most common adverse effects were impotence (4.7% vs. 1.7% placebo), decreased libido (3.0% vs. 1.4% placebo), and ejaculation disorders (1.4% vs. 0.5% placebo) [1]. CNS effects such as dizziness occurred at rates comparable to placebo. The drug does not produce sedation, somnolence, or cognitive impairment at its approved 0.5 mg daily dose.

The Dizziness Overlap That Prescribers Should Monitor

While the pharmacokinetic interaction is minimal, there is one practical overlap worth discussing. Dizziness.

Dutasteride can cause orthostatic dizziness, particularly when co-prescribed with alpha-blockers like tamsulosin. The ARIA trial (N=4,325) found that the dutasteride-tamsulosin combination produced dizziness in 1.4% of subjects vs. 0.7% for dutasteride alone [9]. Benzodiazepines independently cause dizziness and impaired coordination. When all three medications converge in the same patient, additive dizziness becomes a fall-risk concern, especially in men over 65.

The American Geriatrics Society Beers Criteria lists benzodiazepines as potentially inappropriate medications for older adults due to fall risk, cognitive impairment, and delirium [10]. Combining them with any medication that causes dizziness raises the risk profile. This is a pharmacodynamic additive effect, not a drug-drug interaction in the traditional sense, but it is the most clinically relevant consideration when these medications overlap.

Fall risk screening should be standard for any man over 65 taking dutasteride plus a benzodiazepine. Simple interventions include timing the benzodiazepine dose at bedtime, avoiding abrupt position changes, and ensuring adequate home lighting.

What About Strong CYP3A4 Inhibitors Taken Alongside Both Drugs

The interaction picture changes when a true CYP3A4 inhibitor enters the regimen. This is where prescribers need heightened awareness.

The dutasteride FDA label specifically warns that co-administration with CYP3A4 inhibitors may increase dutasteride serum concentrations [1]. A pharmacokinetic study showed that concurrent use of verapamil (a moderate CYP3A4 inhibitor) reduced dutasteride clearance by 37% and increased AUC by 44% [3]. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, and clarithromycin would be expected to produce even larger increases.

If a patient takes dutasteride, a CYP3A4-dependent benzodiazepine (alprazolam or midazolam), and a strong CYP3A4 inhibitor simultaneously, the inhibitor could raise plasma levels of both the dutasteride and the benzodiazepine. The benzodiazepine level increase carries the greater immediate clinical risk because elevated benzodiazepine concentrations directly enhance CNS depression. A meta-analysis in the British Journal of Clinical Pharmacology found that CYP3A4 inhibitors increased midazolam exposure by a median 5.4-fold [11].

The practical guidance: if a patient requires a macrolide antibiotic, azole antifungal, or protease inhibitor while on both dutasteride and a CYP3A4 benzodiazepine, consider switching to lorazepam for the duration of the inhibitor course. Lorazepam's glucuronidation pathway is unaffected by CYP3A4 inhibition.

P-Glycoprotein Considerations

Dutasteride is also a substrate of P-glycoprotein (P-gp), the efflux transporter that limits drug absorption and promotes biliary and renal excretion [1]. Some benzodiazepines, including alprazolam, are P-gp substrates as well [12].

As with CYP3A4, the relevant question is inhibition. Dutasteride does not inhibit P-gp at clinically relevant concentrations [1]. Benzodiazepines are not P-gp inhibitors either. Co-substrate status without mutual inhibition means no clinically meaningful transporter-mediated interaction. However, adding a P-gp inhibitor (such as verapamil, cyclosporine, or amiodarone) to this combination could theoretically increase absorption of both drugs, a scenario analogous to the CYP3A4 inhibitor issue described above.

Dose Adjustment and Monitoring Recommendations

No dose adjustment of either dutasteride or benzodiazepines is required when the two are combined, based on current evidence.

The Endocrine Society clinical practice guidelines for androgen therapy in men do not identify benzodiazepines as contraindicated or requiring dose modification with 5-alpha reductase inhibitors [13]. The FDA label for dutasteride does not list benzodiazepines among drugs requiring dosing changes.

Monitoring should focus on three areas. First, assess for subjective dizziness at follow-up visits, particularly in the first 4 to 6 weeks after starting either drug. Second, if the patient is over 65, screen for fall risk using a validated tool such as the Timed Up and Go test. Third, review the full medication list for any CYP3A4 inhibitors that could transform this low-risk combination into a moderate-risk one.

Patients should be counseled to report any new or worsening drowsiness, unsteadiness, or cognitive slowing. These symptoms would more likely reflect benzodiazepine effects than a dutasteride interaction, but the combination warrants documentation in the medical record.

When to Choose a Non-CYP3A4 Benzodiazepine

For prescribers who want to eliminate even the theoretical CYP3A4 overlap, selecting a glucuronidation-pathway benzodiazepine is straightforward.

Lorazepam (0.5 to 2 mg) provides anxiolysis without CYP3A4 involvement. It is available in oral and injectable forms and has an intermediate half-life of 10 to 20 hours [2]. Oxazepam (10 to 30 mg) offers a similar profile with a slightly shorter duration of action. Temazepam (7.5 to 30 mg) is specifically indicated for insomnia and avoids CYP3A4 metabolism entirely.

This substitution is most valuable in three scenarios: patients taking multiple CYP3A4 substrates, patients with hepatic impairment (where CYP3A4 capacity is already reduced), and patients over 75 with polypharmacy. The FDA safety communication on benzodiazepines emphasizes using the lowest effective dose for the shortest duration in all patients, regardless of concurrent medications [14].